Report

Global Novel Vaccine Delivery System Market Size study, by Delivery Mode (intradermal, subcutaneous, intramuscular, and other), by Device (Syringe, Needle-Free, Injection System and other) and Regional Forecasts 2021-2027

  • Publish Date: Mar,2022
  • Report ID: QI037
  • Page : 250
  • Report Type : PDF (Email)
Global Novel Vaccine Delivery System Market to reach USD XX billion by 2027.
Global Novel Vaccine Delivery System Market is valued at approximately USD XX Billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2021-2027. Vaccines generally consist of a disease-causing germ-like agent, produced through inactive or weakened microorganisms, their toxins, or one of the surface proteins. Through these agents, the immune system recognizes the agent as threat, providing antibodies to protect the body from real or active or stronger germ that may harm the body. Vaccines are provided to different age groups to strengthen their immune system, keeping them safe from certain kinds of infections and diseases throughout the life. Novel Vaccine Delivery comprises of formulations, technologies, methods, and systems to transfer an active pharmaceuticals ingredient in the body, as required, to safely complete its therapeutic effect. Growing immunization programs and their increasing coverage is expected to fuel the Novel Vaccine Delivery System Market. Increasing government support and investment is also propelling the market growth. . For instance, in August 2020, Hindustan Syringes & Medical Devices Ltd. (HMD) announced that it has received an order of 140 million auto disabled syringes for COVID-19 from the Unites Nations Children's Fund (UNICEF). Moreover, several key players are taking strategic initiatives to expand their presence in the market for instance
In July, 2020, Retractable technologies entered into Technology Investment Agreement (TIA) , that is of USD 53.6 million with the United States government, aiming to expand its domestic production of needles and syringes.

However, high cost and unaffordability of safety syringes may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global Novel Vaccine Delivery System Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World (ROW). Asia-Pacific is expected to be the fastest growing market in the forecast period, due to constantly expanding healthcare infrastructure, economic development, are expected to drive the market growth of Novel Vaccine Delivery system market in emerging countries of the region. Also, Asia-Pacific is the most highly populated region across the globe, and increasing population estimates increase in vaccine consumption over time, ultimately boosting novel vaccine delivery market. Supporting the drivers, according to UNICEF India 2020, over 9 million immunization sessions were held across India every year aiming full immunization coverage. The program introduced new vaccines, including the Pneumococcal Conjugate Vaccine (PVC) and Rotavirus Vaccine (RVV).




Major market player included in this report are:

Altaris Capital Partners, LLC
Becton, Dickinson and Company
Carl Zeiss Foundation
Gerresheimer AG
Gurnet Point Capital
Inovio Pharmaceuticals Inc.
Pharmajet Inc.
Retractable Technologies Inc.,
Terumo Corporation
VAXXAS Pty Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Delivery Mode:
Intradermal
Subcutaneous
Intramuscular
Other

By Device:
Syringe
Needle-Free
Injection System
Other

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018-19
Base year - 2019-2020
Forecast period - 2021 to 2027.

Target Audience of the Global Novel Vaccine Delivery System Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors